PROTEIN CHIP MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

The protein chip market is facing significant challenges due to the rise of alternative technologies that are able to perform the same protein analysis functions. Next-generation sequencing has emerged as a powerful competitor to protein chips. NGS is able to analyze thousands of proteins simultaneously at a much lower cost than protein chips. Several studies show that NGS can identify protein-protein interactions and modifications with higher accuracy. It also provides additional genetic information that protein chips cannot match. Many research laboratories are now opting for NGS over protein chips for their proteomics research needs. This is negatively impacting the demand for protein chips. In addition, mass spectrometry has strengthened its position in the protein analysis market in recent years. Technological advances have made mass spectrometers more sensitive and accurate in identifying proteins and quantifying their expression levels. Mass spectrometry does not require separate steps for protein extraction, purification, and labeling like protein chips. This makes mass spectrometry a more streamlined and preferable solution. As reported by the National Institutes of Health in 2022, over 60% of leading academic research centers and pharma companies cited ease-of-use as the top reason for choosing mass spectrometry over protein chips and microarrays for their proteomics studies. With further expected improvements, mass spectrometry is likely to capture an even larger share of the protein analysis market from protein chips.

Market Opportunities: Integration with other omics technologies

Integration with other omics technologies presents a great opportunity for growth in the protein chip market. As the cost of genome sequencing and other ‘omics’ techniques continue to decline significantly, an integrated approach analyzing multiple biomolecular layers of information holds enormous potential for advancing understanding of biology and disease. Protein chips allow analyzing thousands of proteins simultaneously from a single patient sample. Combining protein expression data from chips with genomics, transcriptomics and metabolomics data through integrated analysis can provide novel clinical and research insights. For example, an integrated analysis of transcriptomic and proteomic data from tumor samples has helped identify new protein biomarkers and drug targets for certain cancers. As the scope and affordability of multi-omics studies increases, protein chips are well-positioned to be a key analytical technology supporting such studies. Various public health organizations globally have acknowledged the power of integrated omics approaches for applications like precision medicine and population health research. For instance, the U.S. National Institutes of Health has made multi-omics studies a top funding priority area under its “All of Us” precision medicine initiative from 2020-2023. The initiative aims to collect omics data from over one million participants to better understand health outcomes. Protein chip manufacturers can tap into such large initiatives and clinical studies by offering optimized assay platforms and analysis solutions for integrated profiling of biomolecules from the same sample set. Overall, as multi-omics integration gains greater acceptance among pharmaceutical and biotech companies as well as academia for accelerating disease insights, protein chips are likely to experience increased adoption rates.